Connection

Charles Bennett to Cost-Benefit Analysis

Back to Details
This is a "connection" page, showing publications Charles Bennett has written about Cost-Benefit Analysis.
Charles Bennett
Connection Strength
1.837
Cost-Benefit Analysis
  1. Relationship of Industry Sponsorship to Results of Cost-Effectiveness Analyses of Drugs Used in Breast Cancer Treatment--Reply. JAMA Oncol. 2016 Apr; 2(4):549.
    View in: PubMed
    Score: 0.440
  2. Health economics in the treatment of colorectal cancer. Cancer Invest. 1998; 16(8):582-7.
    View in: PubMed
    Score: 0.124
  3. Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA. Lancet Oncol. 2017 01; 18(1):22-23.
    View in: PubMed
    Score: 0.116
  4. Associations Between Industry Sponsorship and Results of Cost-effectiveness Analyses of Drugs Used in Breast Cancer Treatment. JAMA Oncol. 2016 Feb; 2(2):274-6.
    View in: PubMed
    Score: 0.109
  5. Upping recruitment in clinical trials: are the costs worth it? Onkologie. 2009 Jul; 32(7):378-9.
    View in: PubMed
    Score: 0.069
  6. Responding to a small-scale bioterrorist anthrax attack: cost-effectiveness analysis comparing preattack vaccination with postattack antibiotic treatment and vaccination. Arch Intern Med. 2007 Apr 09; 167(7):655-62.
    View in: PubMed
    Score: 0.059
  7. When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective? J Clin Oncol. 2006 Jul 01; 24(19):2975-7.
    View in: PubMed
    Score: 0.055
  8. Costs and cost effectiveness of a health care provider-directed intervention to promote colorectal cancer screening among Veterans. J Clin Oncol. 2005 Dec 01; 23(34):8877-83.
    View in: PubMed
    Score: 0.054
  9. Cost-effectiveness considerations in the treatment of essential thrombocythemia. Semin Oncol. 2002 Jun; 29(3 Suppl 10):28-32.
    View in: PubMed
    Score: 0.042
  10. Evaluating the financial impact of clinical trials in oncology: results from a pilot study from the Association of American Cancer Institutes/Northwestern University clinical trials costs and charges project. J Clin Oncol. 2000 Aug; 18(15):2805-10.
    View in: PubMed
    Score: 0.037
  11. Cost analyses of adjunct colony stimulating factors for acute leukemia: can they improve clinical decision making. Leuk Lymphoma. 2000 Mar; 37(1-2):65-70.
    View in: PubMed
    Score: 0.036
  12. Comparing cost-effectiveness analyses for the clinical oncology setting: the example of the Gynecologic Oncology Group 111 trial. Cancer Invest. 2000; 18(3):261-8.
    View in: PubMed
    Score: 0.036
  13. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA. 1999 Oct 20; 282(15):1453-7.
    View in: PubMed
    Score: 0.035
  14. Pharmacoeconomics of amifostine in ovarian cancer. Semin Oncol. 1999 Apr; 26(2 Suppl 7):102-7.
    View in: PubMed
    Score: 0.034
  15. The effect of reimbursement policies on the management of Medicare patients with refractory ovarian cancer. Semin Oncol. 1999 Feb; 26(1 Suppl 1):40-5.
    View in: PubMed
    Score: 0.034
  16. Economic analysis of a randomized placebo-controlled phase III study of granulocyte macrophage colony stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia. Eastern Cooperative Oncology Group (E1490). Ann Oncol. 1999 Feb; 10(2):177-82.
    View in: PubMed
    Score: 0.034
  17. Cost-effectiveness model of a phase II clinical trial of a new pharmaceutical for essential thrombocythemia: is it helpful to policy makers? Semin Hematol. 1999 Jan; 36(1 Suppl 2):26-9.
    View in: PubMed
    Score: 0.033
  18. Cost-effectiveness analysis of pegylated-liposomal doxorubicin and liposomal daunorubicin treatments in patients with Kaposi's sarcoma. Acta Oncol. 1999; 38(8):1063-7.
    View in: PubMed
    Score: 0.033
  19. Cost-effectiveness analysis comparing liposomal anthracyclines in the treatment of AIDS-related Kaposi's sarcoma. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Aug 15; 18(5):460-5.
    View in: PubMed
    Score: 0.032
  20. Treating malignant pleural effusions cost consciously. Chest. 1998 Jan; 113(1 Suppl):78S-85S.
    View in: PubMed
    Score: 0.031
  21. Health care economics and bone marrow transplantation. Cancer Treat Res. 1997; 77:377-99.
    View in: PubMed
    Score: 0.029
  22. Economic analyses of phase III cooperative cancer group clinical trials: are they feasible? Cancer Invest. 1997; 15(3):227-36.
    View in: PubMed
    Score: 0.029
  23. Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers? Cancer. 1996 May 01; 77(9):1854-61.
    View in: PubMed
    Score: 0.028
  24. A review of the costs, cost-effectiveness and third-party charges of bone marrow transplantation. Stem Cells. 1996 May; 14(3):312-9.
    View in: PubMed
    Score: 0.028
  25. Free-riding and the prisoner's dilemma: problems in funding economic analyses of phase III cancer clinical trials. J Clin Oncol. 1995 Sep; 13(9):2457-63.
    View in: PubMed
    Score: 0.026
  26. Granulocyte-macrophage colony-stimulating factor as adjunct therapy in relapsed lymphoid malignancy: implications for economic analyses of phase III clinical trials. Stem Cells. 1995 Jul; 13(4):414-20.
    View in: PubMed
    Score: 0.026
  27. Cost-effectiveness models of clinical trials of new pharmaceuticals for AIDS-related Pneumocystis carinii pneumonia: are they helpful to policy makers? Clin Perform Qual Health Care. 1995 Jul-Sep; 3(3):156-64.
    View in: PubMed
    Score: 0.026
  28. Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer. Urology. 1995 Apr; 45(4):633-40.
    View in: PubMed
    Score: 0.026
  29. Sustaining mammography screening among the medically underserved: a follow-up evaluation. J Womens Health (Larchmt). 2015 Apr; 24(4):291-8.
    View in: PubMed
    Score: 0.025
  30. Erythropoietin, a novel repurposed drug: an innovative treatment for wound healing in patients with diabetes mellitus. Wound Repair Regen. 2014 Jan-Feb; 22(1):23-33.
    View in: PubMed
    Score: 0.023
  31. Strategies to improve repeat fecal occult blood testing cancer screening. Cancer Epidemiol Biomarkers Prev. 2014 Jan; 23(1):134-43.
    View in: PubMed
    Score: 0.023
  32. Improving colon cancer screening in community clinics. Cancer. 2013 Nov 01; 119(21):3879-86.
    View in: PubMed
    Score: 0.023
  33. Cost-effectiveness comparison of response strategies to a large-scale anthrax attack on the chicago metropolitan area: impact of timing and surge capacity. Biosecur Bioterror. 2012 Sep; 10(3):264-79.
    View in: PubMed
    Score: 0.021
  34. Costs and cost effectiveness of a health care provider-directed intervention to promote colorectal cancer screening. J Clin Oncol. 2009 Nov 10; 27(32):5370-5.
    View in: PubMed
    Score: 0.018
  35. Costs and cost-effectiveness of a low-intensity patient-directed intervention to promote colorectal cancer screening. J Clin Oncol. 2007 Nov 20; 25(33):5248-53.
    View in: PubMed
    Score: 0.015
  36. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001 Mar 01; 19(5):1519-38.
    View in: PubMed
    Score: 0.010
  37. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Evid Rep Technol Assess (Summ). 1999 May; (4):i-x, 1-246, I1-36, passim.
    View in: PubMed
    Score: 0.009
  38. Economic analyses of new technologies: the case of stem-cell transplantation. J Clin Oncol. 1997 Jan; 15(1):2-4.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.